Trauma is associated with a better prognosis in intensive care patients with Acinetobacter infections
Carregando...
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2014
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER HEIDELBERG
Autores
Citação
INFECTION, v.42, n.1, p.89-95, 2014
Resumo
Acinetobacter baumannii has emerged as a common cause of infection in war-related trauma, civilian trauma and other surgical emergencies. The aim of this study was to determine prognostic factors especially trauma, in critically ill surgical patients with Acinetobacter spp. infection in a reference emergency ICU. A retrospective review of medical records was conducted for all patients admitted to the ICU who developed Acinetobacter spp. infection from January 2007 to December 2009. Bivariate and multivariate analyses were made for 36 patients. The end-point analyzed was the in-hospital mortality. The initial analysis revealed a majority of young (43.6 years +/- A 17.1) men (92 %), trauma victims (78 %) and an in-hospital mortality of 30 %. Patients who had not suffered trauma presented with other surgical conditions and were on average older than trauma patients (57 +/- A 12 versus 40 +/- A 16 years). The overall APACHE II score average was 15.3. The ventilator-associated pneumonia was the main Acinetobacter infection diagnosed. In bivariate analysis lower Glasgow coma scale (p = 0.01) was associated with increased chance of death and being victim of trauma was a protecting factor (OR: 0.16; 95 % CI: 0.03-0.89). Receiving adequate treatment made no difference to outcome (OR: 0.55; 95 % CI: 0.05-3.15). Multivariate analysis showed that only the presence of trauma was independently associated with prognosis and was a protecting factor. Trauma was a marker of good prognosis in emergency ICU patients with Acinetobacter spp. infection.
Palavras-chave
Acinetobacter, Trauma, ICU
Referências
- Blot S, 2003, INTENS CARE MED, V29, P471, DOI 10.1007/s00134-003-1648-8
- Breslow JM, 2011, J NEUROIMMUNE PHARM, V6, P551, DOI 10.1007/s11481-011-9303-6
- Caricato A, 2009, INTENS CARE MED, V35, P1964, DOI 10.1007/s00134-009-1582-5
- Eberle BM, 2010, CRIT CARE MED, V38, P2133, DOI 10.1097/CCM.0b013e3181f17af4
- Erbay A, 2009, INT J ANTIMICROB AG, V34, P575, DOI 10.1016/j.ijantimicag.2009.07.006
- Falagas ME, 2006, CRIT CARE, V10, DOI 10.1186/cc4869
- Garcia-Garmendia JL, 1999, CRIT CARE MED, V27, P1794, DOI 10.1097/00003246-199909000-00015
- Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002
- Howard A, 2012, VIRULENCE, V3, P1
- Iwashkiw JA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002758
- Jang TN, 2009, J HOSP INFECT, V73, P143, DOI 10.1016/j.jhin.2009.06.007
- Kang G, 2010, INFECT CONT HOSP EP, V31, P92, DOI 10.1086/649220
- KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
- Lee NY, 2010, J INFECTION, V61, P219, DOI 10.1016/j.jinf.2010.07.002
- LORTHOLARY O, 1995, CLIN INFECT DIS, V20, P790
- Sebeny PJ, 2008, CLIN INFECT DIS, V47, P444, DOI 10.1086/590568
- TEASDALE G, 1974, LANCET, V2, P81
- Trottier Vincent, 2007, Surg Infect (Larchmt), V8, P437, DOI 10.1089/sur.2006.029
- Tuon FF, 2011, J INFECTION, V62, P246, DOI 10.1016/j.jinf.2011.01.005
- Weingarten CM, 1999, PHARMACOTHERAPY, V19, P1080, DOI 10.1592/phco.19.13.1080.31597